Dr. Farshad Guirakhoo, a virologist by training, was named one of the 50 Most Influential People in Vaccines in VaccineNation’s 2014 list. His most recent assignment was CTO at Vaxess Technologies. Prior to this, he served as CSO at Hookipa Biotech and Executive Director of External R&D at Sanofi Pasteur. Before joining Sanofi Pasteur in 2007, he was with Acambis for 15 years as Head of Research and co-invented the ChimeriVax-technology platform in association with St. Louis University. This platform has successfully been applied in the development of vaccines such as IMOJEV™, PreVenile™, Dengvaxia™, and WN human vaccine. Dr. Guirakhoo has broad experience in the application of gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies, and attenuated viral vectored vaccines for the prevention and treatment of infectious diseases. Dr. Guirakhoo is the author of over 80 peer-reviewed publications and holder of multiple patents.
Application of genetics, gene expression technologies and molecular virology for the constructions and productions of recombinant proteins, human antibodies and attenuated viral vectored vaccines for prevention and treatment of infectious diseases.